Pharma BD Deal Intelligence
Novartis's $5.4B vaccines/diagnostics bet on Chiron never achieved scale profitability and was unwound piece by piece within a decade — diagnostics sold to Grifols (2014), flu vaccines sold to CSL (2015), and the core non-flu vaccines business sold to GSK (2015) alongside a $1.1B impairment charge.
Full analysis, sources & comparables →Novartis's initial $40/share offer for the 58% it didn't own was rejected; analysts viewed Chiron's manufacturing crisis as creating value but flagged…
Novartis closed the $5.4B Chiron acquisition and immediately launched Novartis Vaccines and Diagnostics, framing vaccines as a strategic growth platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Vaccines/blood testing/biopharma; remaining 56% stake at $48/share; entry into vaccines market
Novartis's $5.4B vaccines/diagnostics bet on Chiron never achieved scale profitability and was unwound piece by piece within a decade — diagnostics sold to Grifols (2014), flu vaccines sold to CSL (2015), and the core non-flu vaccines business sold to GSK (2015) alongside a $1.1B impairment charge.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chiron Corporation (this deal) | 2006 | $5.4B | 34 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2006 deals · Novartis AG deals